Skip to Content

Cryo-Cell International Inc CCEL

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. It organized in three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of Prepacyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment which consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. All the business activity of the group is functioned through the United States and it derives revenue from processing and testing fees and storage fees charged each year for storage and through sales of the Prepacyte CB units.

Contact
700 Brooker Creek Boulevard, Suite 1800
Oldsmar, FL, 34677
T +1 813 749-2100
Sector Healthcare
Industry Medical Care Facilities
Most Recent Earnings Nov 30, 2020
Fiscal Year End Nov 30, 2020
Stock Type Speculative Growth
Employees 98